Rapid high-content imaging drives therapeutic success
9 Jun 2025
Araceli Biosciences is on a mission to create cutting-edge imaging platforms that empower researchers to accelerate their therapeutic discovery. In this interview, CEO Matt Beaudet and Product Manager Nasiema Wingate-Pearse discuss the industry shifts shaping their innovations and how the Endeavor™ High Content Screening Platforms address critical research challenges. Learn what distinguishes Araceli’s technology, how they support scientists beyond instrumentation, and what excites them the most about the future of therapeutic research.
See the Endeavour portfolio in action as Dr. Fernanda Garcia Fossa shares her work at the Max Planck Society in this presentation. Plus, request a demo here.
This video was filmed at SLAS Europe 2025.
About the company
Araceli Biosciences
Araceli Biosciences is on a mission to create cutting-edge technologies that empower researchers to accelerate therapeutic discovery. Speed is essential for furthering our understanding of biology and helps in finding better drug candidates with more confidence upstream in the drug discovery pipeline by acquiring high quality data that produce actionable answers. Our goal is to be the leader in predictive AI-based image acquisition and analysis, enabling more informed decisions to increase therapeutic success. We envision a future where patients have earlier access to the most effective treatments.
Related products
Request Quote for All Products
Araceli Endeavor® Ultra High Content Imaging Platform
Araceli BiosciencesThe fastest path to breakthroughs
Araceli Endeavor® Core High Content Imaging Platform
Araceli BiosciencesNo frills, no limits - All essentials starting at 225k
